{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T12:28:17Z","timestamp":1759580897879},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2003,9,1]],"date-time":"2003-09-01T00:00:00Z","timestamp":1062374400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2003,9,1]]},"DOI":"10.1038\/sj.leu.2403035","type":"journal-article","created":{"date-parts":[[2003,9,11]],"date-time":"2003-09-11T14:47:26Z","timestamp":1063291646000},"page":"1827-1833","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease"],"prefix":"10.1038","volume":"17","author":[{"given":"R","family":"Hast","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Hellstr\u00f6m-Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Ohm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Bj\u00f6rkholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F","family":"Celsing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-M","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Dybedal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Gahrton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"L\u00f6fvenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Nilsson-Ehle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J-M","family":"Tangen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Tidefelt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Turesson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Wahlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Wallvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Winquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Bernell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,9,10]]},"reference":[{"key":"BF2403035_CR1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","volume":"89","author":"P Greenberg","year":"1997","unstructured":"Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G et al. International scoring system for evaluating prognosis in myelo-dysplastic syndromes. Blood 1997; 89: 2079\u20132088.","journal-title":"Blood"},{"key":"BF2403035_CR2","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1182\/blood.V98.8.2326","volume":"98","author":"T de Witte","year":"2001","unstructured":"de Witte T, Suciu S, Verhoef G, Labar B, Archimbaud E, Aul C et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001; 98: 2326\u20132331.","journal-title":"Blood"},{"key":"BF2403035_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1365-2141.1991.tb08616.x","volume":"77","author":"P Fenaux","year":"1991","unstructured":"Fenaux P, Morel P, Rose C, Lai JL, Jouet JP, Bauters F . Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br J Haematol 1991; 77: 497\u2013501.","journal-title":"Br J Haematol"},{"key":"BF2403035_CR4","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.1996.14.9.2486","volume":"14","author":"SH Bernstein","year":"1996","unstructured":"Bernstein SH, Brunetto VL, Davey FR, Wurster-Hill D, Mayer RJ, Stone RM et al. Acute myeloid leukemia-type chemotherapy for newly diagnosed patients without antecedent cytopenias having myelodysplastic syndrome as defined by French\u2013American\u2013British criteria: a Cancer and Leukemia Group B Study. J Clin Oncol 1996; 14: 2486\u20132494.","journal-title":"J Clin Oncol"},{"key":"BF2403035_CR5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood.V90.8.2969","volume":"90","author":"E Estey","year":"1997","unstructured":"Estey E, Thall P, Beran M, Kantarjian H, Pierce S, Keating M . Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy. Blood 1997; 90: 2969\u20132977.","journal-title":"Blood"},{"key":"BF2403035_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s002770050285","volume":"74","author":"W Verbeek","year":"1997","unstructured":"Verbeek W, Wormann B, Koch P, Aul C, Hinrichs H, Balleisen L et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol 1997; 74: 205\u2013208.","journal-title":"Ann Hematol"},{"key":"BF2403035_CR7","first-page":"5647","volume":"47","author":"Y Asano","year":"1987","unstructured":"Asano Y, Shibuya T, Okamura S, Yamaga S, Otsuka T, Niho Y . Effect of human recombinant granulocyte\/macrophage colony-stimulating factor and native granulocyte colony-stimulating factor on clonogenic leukemic blast cells. Cancer Res 1987; 47: 5647\u20135648.","journal-title":"Cancer Res"},{"key":"BF2403035_CR8","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1182\/blood.V69.6.1771.1771","volume":"69","author":"E Vellenga","year":"1987","unstructured":"Vellenga E, Young DC, Wagner K, Wiper D, Ostapovicz D, Griffin JD . The effect of GM-CSF and G-CSF in promoting growth of clonogenic cells in acute myeloblastic leukemia. Blood 1987; 69: 1771\u20131776.","journal-title":"Blood"},{"key":"BF2403035_CR9","first-page":"230","volume":"5","author":"SA Cannistra","year":"1991","unstructured":"Cannistra SA, DiCarlo J, Groshek P, Kanakura Y, Berg D, Mayer RJ et al. Simultaneous administration of granulocyte\u2013macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5: 230\u2013238.","journal-title":"Leukemia"},{"key":"BF2403035_CR10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1182\/blood.V77.4.700.700","volume":"77","author":"P Bettelheim","year":"1991","unstructured":"Bettelheim P, Valent P, Andreff M, Tafuri A, Haimi J, Gorischek C et al. Recombinant human granulocyte\u2013macrophage colony-stimulating factor in combination with standard induction chemotherapy in de novo acute myeloid leukemia. Blood 1991; 77: 700\u2013711.","journal-title":"Blood"},{"key":"BF2403035_CR11","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1200\/JCO.1990.8.5.768","volume":"8","author":"AM Gianni","year":"1990","unstructured":"Gianni AM, Gregni M, Siena S, Orazi A, Stern AC, Gandola L et al. Recombinant human granulocyte macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768\u2013778.","journal-title":"J Clin Oncol"},{"key":"BF2403035_CR12","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1200\/JCO.1992.10.8.1266","volume":"10","author":"S Vadhan-Raj","year":"1992","unstructured":"Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C et al. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte\u2013macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level. J Clin Oncol 1992; 10: 1266\u20131277.","journal-title":"J Clin Oncol"},{"key":"BF2403035_CR13","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1056\/NEJM199506223322504","volume":"332","author":"H Dombret","year":"1995","unstructured":"Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia AML Cooperative Study Group. N Engl J Med 1995; 332: 1678\u20131683.","journal-title":"N Engl J Med"},{"key":"BF2403035_CR14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.V86.2.457.bloodjournal862457","volume":"86","author":"JM Rowe","year":"1995","unstructured":"Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA et al. A randomized placebo-controlled phase III study of granulocyte\u2013macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86: 457\u2013462.","journal-title":"Blood"},{"key":"BF2403035_CR15","first-page":"2952","volume":"90","author":"B L\u00f6wenberg","year":"1997","unstructured":"L\u00f6wenberg B, Suciu S, Archimbaud E, Ossenkoppele G, Verhoef GE, Vellenga E et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90: 2952\u20132961.","journal-title":"Blood"},{"key":"BF2403035_CR16","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1182\/blood.V90.12.4710","volume":"90","author":"G Heil","year":"1997","unstructured":"Heil G, Hoelzer D, Sanz MA, Lechner K, Liu Yin JA, Papa G et al. A randomized double-blind placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90: 4710\u20134718.","journal-title":"Blood"},{"key":"BF2403035_CR17","first-page":"2722","volume":"91","author":"F Witz","year":"1998","unstructured":"Witz F, Sadoun A, Perrin MC, Berthou C, Briere J, Cahn JY et al. A placebo-controlled study of recombinant human granulocyte\u2013macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91: 2722\u20132730.","journal-title":"Blood"},{"key":"BF2403035_CR18","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1200\/JCO.2000.18.4.780","volume":"18","author":"JL Harousseau","year":"2000","unstructured":"Harousseau JL, Witz B, Lioure B, Hunault-Berger M, Desablens B, Delain M et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18: 780\u2013787.","journal-title":"J Clin Oncol"},{"key":"BF2403035_CR19","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1056\/NEJM199506223322503","volume":"332","author":"RM Stone","year":"1995","unstructured":"Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte\u2013macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671\u20131677.","journal-title":"N Engl J Med"},{"key":"BF2403035_CR20","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood.V91.10.3607","volume":"91","author":"JE Godwin","year":"1998","unstructured":"Godwin JE, Kopecky KJ, Head DR, Willman CL, Leith CP, Hynes HE et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91: 3607\u20133615.","journal-title":"Blood"},{"key":"BF2403035_CR21","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1038\/sj.leu.2401474","volume":"13","author":"X Thomas","year":"1999","unstructured":"Thomas X, Fenaux P, Dombret H, Delair S, Dreyfus F, Tilly H et al. Granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13: 1214\u20131220.","journal-title":"Leukemia"},{"key":"BF2403035_CR22","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/j.1600-0609.1995.tb00689.x","volume":"54","author":"PB Hansen","year":"1995","unstructured":"Hansen PB, Johnsen HE, Jensen L, Gaarsdal E, Simonsen K, Ralfkiaer E . Priming and treatment with molgramostim (rhGM-CSF) in adult high-risk acute myeloid leukemia during induction chemotherapy: a prospective, randomized pilot study. Eur J Haematol 1995; 54: 296\u2013303.","journal-title":"Eur J Haematol"},{"key":"BF2403035_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1046\/j.1365-2141.1998.00816.x","volume":"102","author":"C Bernasconi","year":"1998","unstructured":"Bernasconi C, Alessandrino EP, Bernasconi P, Bonfichi M, Lazzarino M, Canevari A et al. Randomized clinical study comparing aggressive chemotherapy with or without G-CSF support for high-risk myelodysplastic syndromes or secondary acute myeloid leukaemia evolving from MDS. Br J Haematol 1998; 102: 678\u2013683.","journal-title":"Br J Haematol"},{"key":"BF2403035_CR24","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/sj.leu.2401478","volume":"13","author":"GJ Ossenkoppele","year":"1999","unstructured":"Ossenkoppele GJ, van der Holt B, Verhoef GE, Daenen SM, Verdonck LF, Sonneveld P et al. A randomized study of granulocyte colony-stimulating factor applied during and after chemotherapy in patients with poor risk myelodysplastic syndromes: a report from the HOVON Cooperative Group. Dutch\u2013Belgian Hemato-Oncology Cooperative Group. Leukemia 1999; 13: 1207\u20131213.","journal-title":"Leukemia"},{"key":"BF2403035_CR25","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1182\/blood.V93.8.2478","volume":"93","author":"EH Estey","year":"1999","unstructured":"Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H et al. Randomized phase II study of fludarabine+cytosine arabinoside+idarubicin+\/\u2212all-trans retinoic acid+\/\u2212granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478\u20132484.","journal-title":"Blood"},{"key":"BF2403035_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","volume":"51","author":"JM Bennett","year":"1982","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189\u2013199.","journal-title":"Br J Haematol"},{"key":"BF2403035_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French\u2013American\u2013British Cooperative Group. Ann Intern Med 1985; 103: 620\u2013625.","journal-title":"Ann Intern Med"},{"key":"BF2403035_CR28","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1600-0609.1983.tb00650.x","volume":"31","author":"A st","year":"1983","unstructured":"\u00d6 st A, Lagerl\u00f6f B, Sundstr\u00f6m C, Lindstr\u00f6m P, Gyllenhammer H, Engstedt L et al. A study of the reproducibility of the diagnostic criteria for acute leukaemia. Scand J Haematol 1983; 31: 257\u2013266.","journal-title":"Scand J Haematol"},{"key":"BF2403035_CR29","first-page":"1631","volume":"8","author":"P Bernell","year":"1994","unstructured":"Bernell P, Kimby E, Hast R . Recombinant human granulocyte\u2013macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study. Leukemia 1994; 8: 1631\u20131639.","journal-title":"Leukemia"},{"key":"BF2403035_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/A:1008318930947","volume":"10","author":"CL Bennett","year":"1999","unstructured":"Bennett CL, Stinson TJ, Tallman MS, Stadtmauer EA, Marsh RW, Friedenberg W et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10: 177\u2013182.","journal-title":"Ann Oncol"},{"key":"BF2403035_CR31","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V79.9.2246.2246","volume":"79","author":"E Estey","year":"1992","unstructured":"Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M et al. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte\u2013macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+daunorubicin: comparison to patients treated without GM-CSF. Blood 1992; 79: 2246\u20132255.","journal-title":"Blood"},{"key":"BF2403035_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0002-9440(10)64036-9","volume":"158","author":"S Sugiyama","year":"2001","unstructured":"Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P . Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158: 879\u2013891.","journal-title":"Am J Pathol"},{"key":"BF2403035_CR33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1200\/JCO.1989.7.8.1071","volume":"7","author":"MJ Keating","year":"1989","unstructured":"Keating MJ, Kantarjian H, Smith TL, Estey E, Walters R, Andersson B et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol 1989; 7: 1071\u20131080.","journal-title":"J Clin Oncol"},{"key":"BF2403035_CR34","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1054\/bjoc.1999.1123","volume":"82","author":"M \u00c5str\u00f6m","year":"2000","unstructured":"\u00c5str\u00f6m M, Bodin L, Nilsson I, Tidefelt U . Treatment, long-term outcome and prognostic variables in 214 unselected AML patients in Sweden. Br J Cancer 2000; 82: 1387\u20131392.","journal-title":"Br J Cancer"},{"key":"BF2403035_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S0145-2126(00)00140-5","volume":"25","author":"F Wimazal","year":"2001","unstructured":"Wimazal F, Sperr WR, Kundi M, Meidlinger P, Fonatsch C, Jordan JH et al. Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leukemia Res 2001; 25: 287\u2013294.","journal-title":"Leukemia Res"},{"key":"BF2403035_CR36","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1038\/sj.leu.2402591","volume":"16","author":"M Oosterveld","year":"2002","unstructured":"Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B et al. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia 2002; 16: 1615\u20131621.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/2403035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403035","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/2403035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,10]],"date-time":"2024-01-10T17:39:56Z","timestamp":1704908396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/2403035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,1]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2003,9,1]]}},"alternative-id":["BF2403035"],"URL":"https:\/\/doi.org\/10.1038\/sj.leu.2403035","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,1]]},"assertion":[{"value":"28 January 2003","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2003","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2003","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}